@Article{,
AUTHOR = {M. Skala, T. Rosewall, P. Warde},
TITLE = {Radiation therapy for high-risk prostate cancer – a review},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.3},
PAGES = {28--32},
URL = {http://www.techscience.com/CJU/v12nSuppl.3/63366},
ISSN = {1488-5581},
ABSTRACT = {The term high-risk prostate cancer has been coined to
encompass a group of patients with a poor prognosis
(clinical stage T3/T4, or T1/T2 with PSA > 20 ng/ml or
GS ≥ 8). It is estimated that 20% of patients in Canada
present with high-risk disease, which translates into
approximately 4000 new cases each year. The optimal
management approach is unclear but the standard of care
in North America for this group of patients is radiation
therapy (RT) with prolonged adjuvant hormonal therapy.
Current clinical trials are evaluating the role of local
therapy, the value of RT dose escalation, the potential
benefit of regional lymph node irradiation, the appropriate
duration of adjuvant hormonal therapy, as well as the
possible impact of adjunctive chemotherapy.<br/>
The high-risk group of patients contains a wide spectrum of
disease, ranging from patients with aggressive localized
disease to those with widespread occult distant metastases.
The current challenge facing clinicians is appropriate
treatment selection for individual patients. Information from
novel biomarkers and improved imaging, as well as more
effective local and adjunctive systemic therapies is necessary
to improve outcomes for men with this aggressive disease.},
DOI = {}
}